Log In
BCIQ
Print this Print this
 

larazotide (AT-1001, INN-202, SPD550)

  Manage Alerts
Collapse Summary General Information
Company Alba Therapeutics Corp.
DescriptionTight junction regulator
Molecular Target Zonulin receptor
Mechanism of ActionZonulin receptor antagonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationCeliac disease
Indication DetailsTreat celiac disease
Regulatory Designation U.S. - Fast Track (Treat celiac disease)
PartnerInnovate Biopharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$7.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/29/2016

Undisclosed

Undisclosed

Undisclosed

02/14/2011

Undisclosed

$7.0M

Undisclosed

Get a free BioCentury trial today